Skip to content
Toggle main navigation
More
Open dropdown to see remaining menu items
Log in
Dr Mark Bullimore weighs in on recent FDA marketing authorization of Stellest lenses | Optometry Times - Clinical News & Expert Optometrist Insights
Published on October 1, 2025
Continue reading on website
Other news
Taiwanese Study Using Population-based Polygenic Risk Score Effectively Predicted POAG
October 1, 2025
The most significant locus identified in the genome-wide association study was near the KYNU gene, which hasn’t been reported before in genetic POAG studies. KYNU encodes kynurenine, and the pathway this enzyme plays a key role in has been linked to mitochondrial dysfunction and a range of neurodegenerative conditions—including glaucoma—with reduced levels. Photo: Michael Chaglasian, OD. Click im
EssilorLuxottica Completes Acquisition of Optegra
October 2, 2025
PARIS—EssilorLuxottica (Reuters: ESLX.PA) announced yesterday that it has successfully completed the acquisition of Optegra from MidEuropa. In making the announcement, the company noted that “Optegra is a fast-growing and highly integrated ophthalmology platform operating an extensive network of over 70 eye hospitals and diagnostic facilities.” Under the Optegra, Lexum and Iris brands, the announc
Dr Mark Bullimore weighs in on recent FDA marketing authorization of Stellest lenses | Optometry Times - Clinical News & Expert Optometrist Insights | Edcetera - Optometry